Pharma-Biotech Program Showcases Spanish Innovation and Strengthens Biomedical Collaboration

Connecting research projects from scientific centers and small start-ups and spin-offs with pharmaceutical companies is the goal of the Pharma-Biotech program, an initiative launched by Farmaindustria in 2011 that has since evaluated more than a thousand proposals to boost the development of new medicines.

With this objective in mind, the 26th Pharma-Biotech Cooperation Meeting was held this Wednesday, where seven researchers from Spain presented their progress to representatives from seven pharmaceutical companies. This year, the research projects presented focused on oncology, obesity, nephrology, and hepatology.

Pharma-Biotech is connecting researchers, start-ups, and pharma to advance cutting-edge medicines in Spain

“We select projects that stand out for their innovation and level of maturity , which allows us to study possible collaboration agreements with the industry under advantageous technical and economic conditions,” recalls Amelia Martín Uranga, Director of Clinical and Translational Research at Farmaindustria.

The Pharma-Biotech program fosters the efficient exchange of information and direct contact between scientific and business stakeholders, and helps identify opportunities to transform Spanish biomedical research into economic and social value. “Building bridges between basic research and the development of new medicines is key to strengthening Spain’s role as a global biomedical innovation platform,” emphasized Martín Uranga, in line with the goals set out in the Pharmaceutical Industry Strategy 2024-2028.

“The major challenge is identifying knowledge wherever it may be and assuming the high cost of developing that potential, which carries a high risk of failure,” he added.

In this regard, the head of Clinical and Translational Research at Farmaindustria emphasizes the importance of increasing public investment in biomedical research: “In addition to pharmaceutical companies, public funding is key in the early stages of drug or therapy development. When sufficient data has not yet been generated to secure funding from private investors, the presence of public funds that understand the characteristics of these companies is crucial.”

This 26th Pharma-Biotech Cooperation Meeting was the second held this year. The first took place in July in Barcelona and was organized in collaboration with Biocat, with the aim of further strengthening the BioRegion of Catalonia and promoting the development of new medicines and more efficient public-private partnership models, given that translational research is a strategic priority for Farmaindustria to foster the research ecosystem in Spain.

__

(Featured image by Lightsaber Collection via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in elglobalfarma. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.